Effect of Prednisolone Therapy on Hand Osteoarthritis Patients with Synovitis
DOI: 10.23977/medsc.2020.010101 | Downloads: 5 | Views: 1309
Xue Han 1, Jianjun Li 2, Ningning Liu 2
1 Operation room, Binzhou People’s Hospital, Binzhou, Shandong, China, 256600
2 Orthopaedics, Binzhou People’s Hospital, Binzhou, Shandong, China, 256600
Corresponding AuthorXue Han
Objective: To study the clinical effect of short-term prednisolone therapy on patients with hand osteoarthritis accompanied by synovitis. Methods: From December 2017 to December 2019, 80 patients with synovitis diagnosed with hand osteoarthritis were randomly divided into 2 groups according to different treatment schemes, 40 cases in each group: Prednisone treatment group (group P: 5 mg/ mL /time/day, 2 ml, oral) and placebo group (group C: 2 mL /time/day, placebo, oral) continued this regimen for 6 weeks. The patients in group P were changed to 5 mg/mL/time/day, and after 1 week of continuous medication, the dosage was changed to 2.5 mg/day and continued to be used for 1 week, and the medication was stopped. Group C changed the placebo dosage according to group P. Observed from the 9th to the 14th week, a total of 6 weeks. The joint swelling, visual analogue score (VAS score), salvage analgesic drug use, joint function score, and serum C-reactive protein (CRP) levels were recorded in both groups. Results: All patients completed the 14-week trial and follow-up. The recorded results are as follows: the VAS scores of the hand bone joints of the two groups were compared with those before treatment (T0). The VAS scores were 6 weeks (T1) and 8 weeks (T2). The pain was relieved, and the difference was statistically significant (P<0.05). After receiving prednisolone treatment, the swelling of the hand joints in group P was reduced at T1 and T2, and the joint function score was decreased at T1 and T2. Serum CRP level was reduced at T1 and T2, the difference was statistically significant (P<0.05). Compared with group C, the pain in group P was reduced at T1 and T2, the degree of joint swelling was reduced at T1 and T2, the joint function score was decreased at T1 and T2, and the serum CRP level was reduced at T1 and T2. The difference was statistically significant (P<0.05); the use of salvage analgesics in group P was 1 and 2 at T1 and T2, respectively, and the use of salvage analgesics in group C was 7 and 12 at T1 and T2, respectively, the difference between the two groups was statistically significant (P<0.05). One case of gastrointestinal discomfort occurred in group C (2.50%); one case of gastrointestinal discomfort occurred in group P(2.50%), two cases of elevated blood glucose(5.00%), and one case of rash(2.50%). There was no significant difference in the occurrence of adverse reactions between the two groups (P>0.05). Conclusion: The short-term treatment of prednisolone can significantly improve the pain symptoms of hand osteoarthritis, reduce the synovitis reaction, and there are no obvious adverse events, which can effectively improve hand joint function.
KEYWORDSHand osteoarthritis, Synovitis, Prednisolone
CITE THIS PAPER
Xue Han, Jianjun Li, Ningning Liu, Effect of Prednisolone Therapy on Hand Osteoarthritis Patients with Synovitis. MEDS Clinical Medicine (2020) 1: 1-8. DOI: http://dx.doi.org/10.23977/medsc.2020.010101.
 Bijlsma JW, Berenbaum F, Lafeber FP, et al. (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet, 377(9783), 2115-2126.
 Branco JC, Rodrigues AM, Gouveia N, et al. (2016) Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from Epi Reuma Ptanational health survey. RMD Open, 2(1), 166-168.
 RLiu, WDamman, M Reijnierse, et al. (2017) Bone marrow lesions on magnetic resonance imaging in hand osteoarthritis are associated with pain and interact with synovitis. Osteoarthritis and cartilage, 25(7): 1093-1099.
 Qin J, Barbour KE, Murphy LB, et al. (2017) Lifetime risk of symptomatic hand osteoarthritis: the Johnston County osteoarthritis project. Arthritis Rheumatol, 69(6): 1204-1212.
 Pham T, van der Heijde D, Altman RD, et al. (2004) OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage, 12(5), 389-399.
 Kvien TK, Fjeld E, Slatkowsky-Christensen B, et al. (2008) Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann Rheum Dis, 67(7), 942-948.
 Altman R，Alarcon G，Appelrouth D，et al. (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum, 33(2), 1601-1610.
 Marshall M, Watt FE, Vincent TL, et al. (2018) Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol, 14(11), 641-656.
 Kroon FPB, Carmona L, Schoones JW, et al. (2018) Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of handosteoarthritis. RMD Open, 4(2), 734-736.
 Claire Y J, Elizabeth MA, Andrew J, et al. (2012) A randomized, double-blind, placebo-controlled trial of low-dose oral prednisolone for treating painful hand osteoarthritis. Rheumatology (Oxford, England), 51(12), 2286-2294.
 Kloppenburg M, Kroon FP, Blanco FJ, et al. (2019) 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis, 78(1), 16-24.
 Smith TO, Zou K, Abdullah N, et al. (2016) Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? Asystematic review and meta-analysis. Ann Rheum Dis, 75(11), 1971-1978.
 Haugen IK, Østergaard M, Eshed I, et al. (2014) Iterative development and reliability of the OMERACT hand osteoarthritis MRI scoring system. J Rheumatol, 41(2), 386-391.
 Spolidoro NO, Natour J, Machado FS, et al. (2015) Effectiveness of triamcinolone hexacetonide intraarticular injection in interphalangeal joints: a 12-week randomized controlledtrialin patients with handosteoarthritis. J Rheumatol, 42(10), 1869-1877.
 Kloppenburg M, vanBeest S, Kroon FPB. Thumbbaseosteoarthritis: ahandosteoarthritissubsetrequiringadistinct approach. Best Pract Res Clin Rheumatol, 31(4), 649-760.
 Duru N, van der Goes MC, Jacobs JW, et al. (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-doseglucocorticoid therapy inrheumatic diseases. Ann Rheum Dis, 72(12), 1905-1913.
 Bhala N, Emberson J, Merhi A, et al. (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet, 382(9894), 769-779.
 Zhang Y, Niu J, Kelly-Hayes M, et al. (2002) Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: the Framingham Study. Am J Epidemiol, 156(11), 1021-1027.
 Zhang W, Doherty M, Leeb BF, et al. (2009) EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis, 68(1), 8-17.
 Altman R, Alarcón G, Appelrouth D, et al. (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum, 33(5), 1601-1610.
 Keen HI, Lavie F, Wakefield RJ, et al. (2008) The development of a preliminary ultrasonographic scoring system for features of hand osteoarthritis. Ann Rheum Dis, 67(2), 651-655.